This Billionaire Investor Is 'Thrilled' to Own Kenvue Stock Despite Tylenol Turbulence. Should You Buy KVUE Here?

Despite a 28% YTD drop in KVUE stock due to Tylenol controversy, investor Jeff Smith is optimistic after rapid leadership changes. Interim CEO Perry aims for a turnaround, addressing operational challenges and brand focus to improve Kenvue's performance.